Xgeva是什么药品呢？

What kind of medicine is it? Xgeva is a RANK ligand (RANKL) inhibitor produced by Amgen. Xgeva is used to treat osteoporosis in menopausal women who are at high risk for fracture. Xgeva is used to treat bone loss caused by androgen deprivation therapy in patients with prostate cancer. .

Xgeva is a drug for the treatment of breast cancer in middle-aged and elderly postmenopausal women. However, this drug is not only able to treat female breast cancer. It also has a good therapeutic effect on osteoporosis in some postmenopausal women. Xgeva has conducted relevant medical trials for the treatment of osteoporosis in postmenopausal women. During the extended trial, all women must receive Xgeva 60mg treatment once every six months in addition to taking daily calcium tablets and vitamin D. Let's see how this experiment works.

The results showed that at the completion of the second year of the extension trial, the long-term group was treated with a total of 10 doses (a total of 5 years), and the initial treatment group was treated with a total of 4 doses (a total of 2 years). In the long-term group, at the fourth and fifth years of treatment, their lumbar spine bone mineral density (BMD) increased by 1.9% and 1.7% respectively, and their total hip BMD increased by 0.7% and 0.6% (compared with the baseline at the beginning of the extension study); at the fifth year of treatment, the cumulative increases in lumbar spine and total hip BMD of patients in this group were 13.7% and 7%, respectively. During 2 years of treatment, patients in the treatment-naïve group experienced increases in lumbar spine and total hip BMD of 7.9% and 4.1%, respectively (compared to baseline at the start of the extension study).